Table 3.
Laboratory data
| Measurement | Baseline | 12 Weeks | P Value |
|---|---|---|---|
| Renal Function and Electrolytes | |||
| Creatinine, mg/dl | |||
| 6R-BH4 group | 1.81 ± 0.09 | 1.75 ± 0.11 | 0.346 |
| Placebo group | 1.62 ± 0.07 | 1.62 ± 0.05 | 1.000 |
| Blood urea nitrogen, mg/dl | |||
| 6R-BH4 group | 21 ± 2 | 19 ± 2 | 0.276 |
| Placebo group | 17 ± 2 | 17 ± 2 | 0.969 |
| Potassium, mg/dl | |||
| 6R-BH4 group | 4.0 ± 0.1 | 3.8 ± 0.1 | 0.025 |
| Placebo group | 3.6 ± 0.2 | 3.7 ± 0.1 | 0.682 |
| Urinary microalbumin:creatinine, mg/g | |||
| 6R-BH4 group | 148 ± 54 | 157 ± 40 | 0.348 |
| Placebo group | 163 ± 58 | 137 ± 61 | 0.278 |
| Progenitor Cells | |||
| CD34+, cells/μl | |||
| 6R-BH4 group | 4.17 ± 0.94 | 3.94 ± 0.71 | 0.898 |
| Placebo group | 3.07 ± 0.71 | 3.09 ± 0.63 | 0.898 |
| CD34+/CD133+, cells/μl | |||
| 6R-BH4 group | 2.00 ± 0.40 | 1.97 ± 0.39 | 0.966 |
| Placebo group | 1.74 ± 0.44 | 1.64 ± 0.38 | 0.831 |
| CD34+/VEGF2R+, cells/μl | |||
| 6R-BH4 group | 0.05 ± 0.01 | 0.01 ± 0.006 | 0.813 |
| Placebo group | 0.04 ± 0.009 | 0.03 ± 0.006 | 0.759 |
| CD34+/CD133+/VEGF2R+, cells/μl | |||
| 6R-BH4 group | 0.01 ± 0.006 | 0.01 ± 0.004 | 0.389 |
| Placebo group | 0.01 ± 0.004 | 0.02 ± 0.004 | 0.344 |
Values are expressed as the means ± SE.
VEGF2R, vascular endothelial growth factor 2 receptor. A significant P value is shown in bold.